BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 24976721)

  • 1. Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects.
    Neureiter D; Jäger T; Ocker M; Kiesslich T
    World J Gastroenterol; 2014 Jun; 20(24):7830-48. PubMed ID: 24976721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic targeting in pancreatic cancer.
    van Kampen JG; Marijnissen-van Zanten MA; Simmer F; van der Graaf WT; Ligtenberg MJ; Nagtegaal ID
    Cancer Treat Rev; 2014 Jun; 40(5):656-64. PubMed ID: 24433955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current clinical trials for epigenetic targets and therapeutic inhibitors for pancreatic cancer therapy.
    Ganji C; Farran B
    Drug Discov Today; 2022 May; 27(5):1404-1410. PubMed ID: 34952224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel therapeutic targets for pancreatic cancer.
    Tang SC; Chen YC
    World J Gastroenterol; 2014 Aug; 20(31):10825-44. PubMed ID: 25152585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The promise of epigenomic therapeutics in pancreatic cancer.
    Lomberk GA; Iovanna J; Urrutia R
    Epigenomics; 2016 Jun; 8(6):831-42. PubMed ID: 27337224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant epigenetic regulation: a central contributor to lung carcinogenesis and a new therapeutic target.
    Juergens RA; Rudin CM
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic alterations as biomarkers in pancreatic ductal adenocarcinoma.
    Syren P; Andersson R; Bauden M; Ansari D
    Scand J Gastroenterol; 2017; 52(6-7):668-673. PubMed ID: 28301276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations of Epigenetic Regulators in Pancreatic Cancer and Their Clinical Implications.
    Silverman BR; Shi J
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance?
    Ciernikova S; Earl J; García Bermejo ML; Stevurkova V; Carrato A; Smolkova B
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32521716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
    Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
    Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy.
    Vitale G; Dicitore A; Messina E; Sciammarella C; Faggiano A; Colao A
    Recent Pat Anticancer Drug Discov; 2016; 11(3):275-82. PubMed ID: 27306881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential methylation landscape of pancreatic ductal adenocarcinoma and its precancerous lesions.
    Bararia A; Dey S; Gulati S; Ghatak S; Ghosh S; Banerjee S; Sikdar N
    Hepatobiliary Pancreat Dis Int; 2020 Jun; 19(3):205-217. PubMed ID: 32312637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic Targets and their Inhibitors in Cancer Therapy.
    Zhao L; Duan YT; Lu P; Zhang ZJ; Zheng XK; Wang JL; Feng WS
    Curr Top Med Chem; 2018; 18(28):2395-2419. PubMed ID: 30582481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNMT1 as a therapeutic target in pancreatic cancer: mechanisms and clinical implications.
    Wong KK
    Cell Oncol (Dordr); 2020 Oct; 43(5):779-792. PubMed ID: 32504382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies.
    Matsuoka T; Yashiro M
    World J Gastroenterol; 2016 Jan; 22(2):776-89. PubMed ID: 26811624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications of cell-of-origin epigenetic characteristics in non-functional pancreatic neuroendocrine tumors.
    Dreijerink KM; Hackeng WM; Singhi AD; Heaphy CM; Brosens LA
    J Pathol; 2022 Feb; 256(2):143-148. PubMed ID: 34750813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Development of Epigenetics and Related Inhibitors for Targeted Drug Design in Cancer Therapy.
    Liu N; Zhao R; Ma Y; Wang D; Yan C; Zhou D; Yin F; Li Z
    Curr Top Med Chem; 2018; 18(28):2380-2394. PubMed ID: 30430946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward.
    Khan MA; Azim S; Zubair H; Bhardwaj A; Patel GK; Khushman M; Singh S; Singh AP
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28383487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.
    Sahin IH; Lowery MA; Stadler ZK; Salo-Mullen E; Iacobuzio-Donahue CA; Kelsen DP; O'Reilly EM
    Expert Rev Gastroenterol Hepatol; 2016 Aug; 10(8):893-905. PubMed ID: 26881472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathobiology of pancreatic cancer: implications on therapy.
    Regel I; Hausmann S; Benitz S; Esposito I; Kleeff J
    Expert Rev Anticancer Ther; 2016; 16(2):219-27. PubMed ID: 26652651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.